Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2016

Open Access 01-04-2016 | Original Article

Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer

Authors: A. Gasiorowska, R. Talar-Wojnarowska, A. Kaczka, A. Borkowska, L. Czupryniak, E. Małecka-Panas

Published in: Digestive Diseases and Sciences | Issue 4/2016

Login to get access

Abstract

Background

Recent studies have suggested that various cytokines may be important players in the development and progression of chronic pancreatitis (CP) and pancreatic adenocarcinoma (PC).

Aims

We studied endothelial dysfunction and subclinical inflammation in patients with newly diagnosed pancreatic adenocarcinoma and CP.

Methods

A total of 45 patients were included in the present investigation, 27 with CP and 18 with PC. In addition, the study included 13 age- and body weight-matched healthy subjects served as controls. In all subjects, plasma adiponectin, TNF-alfa, interleukin 6 (IL-6), interleukin 1beta (IL-1β), E-selectin, thrombomodulin, adhesion molecules ICAM and VCAM, and endothelin-1 were assessed.

Results

PC and CP patients as compared with controls had significantly greater plasma adiponectin (13,292 and 12,227 vs 5408 ng/ml; p < 0.0003), TNF-alfa (22.1 and 23.1 vs 13 pg/ml; p < 0.0002), and IL-6 (6.6 and 7.3 vs 3.3 pg/ml; p < 0.0001). Moreover, there was significantly higher concentration of ICAM (931 and 492 vs 290 ng/ml; p < 0.005) and VCAM (1511 and 1080 vs 840 ng/ml; p < 0.01) in PC and CP patients. When PC and CP patients with and without diabetes were considered separately, there was no difference in adiponectin, cytokines, and parameters of endothelial dysfunction.

Conclusion

In summary, our data indicate that patients with CP and PC express high levels of several cytokines compared with healthy individuals, especially adiponectin, TNF-α and IL-6. Serum TNF-α and ICAM concentrations coordinately increase in advanced CP. Furthermore, especially in PC subjects, elevated markers of endothelial dysfunction are present. This study provides additional evidence that changes in inflammatory cytokine and adhesion molecules in PC and CP are not likely related to endocrine disorders.
Literature
2.
go back to reference Kate M, Hofland LJ, Koetsveld PM, Jeekel J, Eijck CJ. Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothelial Cell Interact J Pancreas. 2006;7:454–464. Kate M, Hofland LJ, Koetsveld PM, Jeekel J, Eijck CJ. Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothelial Cell Interact J Pancreas. 2006;7:454–464.
3.
go back to reference Emmrich J, Weber I, Nausch M, et al. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma. Digestion. 1998;59:192–198.CrossRefPubMed Emmrich J, Weber I, Nausch M, et al. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma. Digestion. 1998;59:192–198.CrossRefPubMed
4.
go back to reference Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319–328.CrossRefPubMed Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319–328.CrossRefPubMed
5.
go back to reference Ebrahimi B, Tucker SL, Donghui L, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727–2736.CrossRefPubMed Ebrahimi B, Tucker SL, Donghui L, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727–2736.CrossRefPubMed
6.
go back to reference van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH. The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas. 2006;32:396–402.CrossRefPubMed van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH. The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas. 2006;32:396–402.CrossRefPubMed
7.
go back to reference Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179–187.CrossRefPubMed Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179–187.CrossRefPubMed
8.
go back to reference Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44:534–541.CrossRefPubMedPubMedCentral Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44:534–541.CrossRefPubMedPubMedCentral
10.
go back to reference Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120:682–707.CrossRefPubMed Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120:682–707.CrossRefPubMed
11.
12.
go back to reference Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334.CrossRefPubMed Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334.CrossRefPubMed
13.
go back to reference Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–214.CrossRefPubMed Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–214.CrossRefPubMed
14.
go back to reference Dima SO, Tanase C, Albulescu R, et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012;41:1001–1007.CrossRefPubMed Dima SO, Tanase C, Albulescu R, et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012;41:1001–1007.CrossRefPubMed
15.
go back to reference Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–355.CrossRefPubMed Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–355.CrossRefPubMed
16.
go back to reference Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–1107.CrossRefPubMed Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–1107.CrossRefPubMed
17.
go back to reference Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–472.CrossRefPubMed Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–472.CrossRefPubMed
18.
go back to reference Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–1694.CrossRefPubMed Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–1694.CrossRefPubMed
19.
go back to reference Chang MC, Chang YT, Su TC, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007;35:16–21.CrossRefPubMed Chang MC, Chang YT, Su TC, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007;35:16–21.CrossRefPubMed
20.
go back to reference Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes Control. 2009;20:625–633.CrossRefPubMedPubMedCentral Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes Control. 2009;20:625–633.CrossRefPubMedPubMedCentral
21.
go back to reference Bao Y, Giovannucci EL, Kraft P, et al. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomark Prev. 2013;22:855–861.CrossRef Bao Y, Giovannucci EL, Kraft P, et al. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomark Prev. 2013;22:855–861.CrossRef
22.
go back to reference Grote VA, Rohrmann S, Dossus L, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int. J. Cancer. 2012;130:2428–2437.CrossRefPubMed Grote VA, Rohrmann S, Dossus L, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int. J. Cancer. 2012;130:2428–2437.CrossRefPubMed
23.
go back to reference Krechler T, Zeman M, Vecka M, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma. 2011;1:58–64.CrossRef Krechler T, Zeman M, Vecka M, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma. 2011;1:58–64.CrossRef
24.
go back to reference Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet. 2003;362:1431–1432.CrossRefPubMed Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet. 2003;362:1431–1432.CrossRefPubMed
25.
go back to reference Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008;114:275–288.CrossRefPubMed Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008;114:275–288.CrossRefPubMed
26.
go back to reference Pezzilli R, Barassi A, Corsi MM, et al. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45:93–99.CrossRefPubMed Pezzilli R, Barassi A, Corsi MM, et al. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45:93–99.CrossRefPubMed
27.
go back to reference Nikiteas N, Tzanakis N, Gazouli M, et al. Serum Il-6, TN F alpha and CRP levels in Greek colorectal cancer patients: prognosis implications. World J Gastroenterol. 2005;11:1639–1643.CrossRefPubMedPubMedCentral Nikiteas N, Tzanakis N, Gazouli M, et al. Serum Il-6, TN F alpha and CRP levels in Greek colorectal cancer patients: prognosis implications. World J Gastroenterol. 2005;11:1639–1643.CrossRefPubMedPubMedCentral
28.
go back to reference Pftizenmaier J, Vessella R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211–1216.CrossRef Pftizenmaier J, Vessella R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211–1216.CrossRef
29.
30.
go back to reference Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Małecka-Panas E. Tumor necrosis factor α and interferon γ genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;1:56–62.CrossRef Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Małecka-Panas E. Tumor necrosis factor α and interferon γ genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;1:56–62.CrossRef
31.
go back to reference Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998;28:12–15.CrossRefPubMed Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998;28:12–15.CrossRefPubMed
32.
go back to reference Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83–89.CrossRefPubMed Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83–89.CrossRefPubMed
33.
go back to reference Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001;21:1355–1358.PubMed Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001;21:1355–1358.PubMed
34.
go back to reference Bemelmans MA, Gouma DJ, Greve JW, Burman WA. Cytokines, tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology. 1992;15:1132–1136.CrossRefPubMed Bemelmans MA, Gouma DJ, Greve JW, Burman WA. Cytokines, tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology. 1992;15:1132–1136.CrossRefPubMed
35.
go back to reference Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest. 2000;30:1107–1112.CrossRefPubMed Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest. 2000;30:1107–1112.CrossRefPubMed
36.
go back to reference Cardellini M, Andreozzi F, Laratta E, et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes Metab Res Rev. 2007;23:141–145.CrossRefPubMed Cardellini M, Andreozzi F, Laratta E, et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes Metab Res Rev. 2007;23:141–145.CrossRefPubMed
37.
go back to reference Teros T, Hakala R, Ylinen L, et al. Cytokine balance and lipid antigen presentation in the NOD mouse pancreas during development of insulitis. Pancreas. 2000;20:191–196.CrossRefPubMed Teros T, Hakala R, Ylinen L, et al. Cytokine balance and lipid antigen presentation in the NOD mouse pancreas during development of insulitis. Pancreas. 2000;20:191–196.CrossRefPubMed
38.
go back to reference Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediat Inflamm. 2006;1:1–6.CrossRef Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediat Inflamm. 2006;1:1–6.CrossRef
39.
go back to reference Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute phase proteins but not TNF-α or its receptors. Diabetologia. 2002;45:805–812.CrossRefPubMed Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute phase proteins but not TNF-α or its receptors. Diabetologia. 2002;45:805–812.CrossRefPubMed
40.
go back to reference Hansen M, Nielsen AR, Vilsbøll T, et al. Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. Pancreas. 2012;41:1316–1318.CrossRefPubMed Hansen M, Nielsen AR, Vilsbøll T, et al. Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. Pancreas. 2012;41:1316–1318.CrossRefPubMed
41.
go back to reference Shah N, Siriwardena AK. Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. World J Gastroenterol. 2013;19:4001–4006.CrossRefPubMedPubMedCentral Shah N, Siriwardena AK. Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. World J Gastroenterol. 2013;19:4001–4006.CrossRefPubMedPubMedCentral
42.
go back to reference Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki R. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas. 1999;1:96–103.CrossRef Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki R. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas. 1999;1:96–103.CrossRef
43.
go back to reference Ali S, Kaur J, Patel KD. Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol. 2000;157:313–321.CrossRefPubMedPubMedCentral Ali S, Kaur J, Patel KD. Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol. 2000;157:313–321.CrossRefPubMedPubMedCentral
44.
go back to reference Tang WW, Stelter AA, French S, et al. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Modern Pathology. 2007;20:509–513.CrossRefPubMed Tang WW, Stelter AA, French S, et al. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Modern Pathology. 2007;20:509–513.CrossRefPubMed
45.
go back to reference Markocka-Maczka K. Concentration of serum soluble forms of ICAM-1 (sVCAM-1) and VCAM-1 (sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma. Wiad Lek. 2003;56:147–151.PubMed Markocka-Maczka K. Concentration of serum soluble forms of ICAM-1 (sVCAM-1) and VCAM-1 (sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma. Wiad Lek. 2003;56:147–151.PubMed
46.
go back to reference Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) Expression and serum levels in pancreatic cancer. PlosOne. 2012;6:e39018.CrossRef Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) Expression and serum levels in pancreatic cancer. PlosOne. 2012;6:e39018.CrossRef
47.
go back to reference Sakamoto H, Kimura H, Sekijima M, et al. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Jpn J Clin Oncol. 2012;42:105–112.CrossRefPubMed Sakamoto H, Kimura H, Sekijima M, et al. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Jpn J Clin Oncol. 2012;42:105–112.CrossRefPubMed
48.
go back to reference Torer N, Kayaselcuk F, Nursal TZ, et al. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol. 2007;96:419–423.CrossRefPubMed Torer N, Kayaselcuk F, Nursal TZ, et al. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol. 2007;96:419–423.CrossRefPubMed
49.
go back to reference Tempia-Caliera AA, Horvath LZ, Zimmermann A, et al. Adhesion molecules in human pancreatic cancer. J Surg Oncol. 2002;79:93–100.CrossRefPubMed Tempia-Caliera AA, Horvath LZ, Zimmermann A, et al. Adhesion molecules in human pancreatic cancer. J Surg Oncol. 2002;79:93–100.CrossRefPubMed
50.
go back to reference Hong X, Michalski CW, Kong B, et al. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol. 2010;101:564–569.CrossRefPubMed Hong X, Michalski CW, Kong B, et al. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol. 2010;101:564–569.CrossRefPubMed
51.
go back to reference Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol. 2003;9:368–372.CrossRefPubMedPubMedCentral Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol. 2003;9:368–372.CrossRefPubMedPubMedCentral
52.
go back to reference Sawada T, Ho JJ, Chung YS, Sowa M, Kim YS. E-selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer. 1994;15:901–907.CrossRef Sawada T, Ho JJ, Chung YS, Sowa M, Kim YS. E-selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer. 1994;15:901–907.CrossRef
53.
go back to reference Nakchbandi IA, Lohr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastrol Hepatol. 2008;8:445–455.CrossRef Nakchbandi IA, Lohr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastrol Hepatol. 2008;8:445–455.CrossRef
54.
go back to reference Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531–2539.CrossRefPubMed Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531–2539.CrossRefPubMed
55.
go back to reference Lindahl AK, Boffa MC, Abildqaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost. 1993;69:112–114.PubMed Lindahl AK, Boffa MC, Abildqaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost. 1993;69:112–114.PubMed
Metadata
Title
Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer
Authors
A. Gasiorowska
R. Talar-Wojnarowska
A. Kaczka
A. Borkowska
L. Czupryniak
E. Małecka-Panas
Publication date
01-04-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3972-6

Other articles of this Issue 4/2016

Digestive Diseases and Sciences 4/2016 Go to the issue

DDS-GRG Profiles and Perspectives

GRG Profiles: George Triadafilopoulos

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine